Unicycive Therapeutics Presents at ASN Kidney Week 2024
Unicycive Therapeutics Announces Poster Presentations
Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a biotechnology company focusing on the treatment of kidney diseases, has announced the presentation of three posters detailing their product candidates at the American Society of Nephrology (ASN) Kidney Week 2024. This event, a key platform for sharing advancements in nephrology, will occur from October 24-27, 2024.
Highlights of the Presentations
The posters will cover significant studies involving oxylanthanum carbonate (OLC) and UNI-494, which are garnering considerable interest from the medical community. Shalabh Gupta, MD, Chief Executive Officer of Unicycive, expressed excitement about presenting at this notable meeting in the field.
Details of the Poster Presentations
The following titles and authors will be featured at the event:
- Title: Intravenous UNI-494 Slows the Progression or Halts/Reverses Acute Kidney Injury When Administered After Ischemia/Reperfusion in Rats
- Lead Author: Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive
- Session Title: AKI: Mechanisms
- Poster Board: #FR-PO155
- Date/Time: October 25, 2024, from 10:00 a.m. – 12:00 p.m. PT
- Title: Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rat
- Lead Author: Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive
- Session Title: CKD-MBD: Basic and Translational
- Poster Board: #SA-PO243
- Date/Time: October 26, 2024, from 10:00 a.m. – 12:00 p.m. PT
- Title: UNI-494 Phase I Safety, Tolerability, and Pharmacokinetics
- Lead Author: Guru Reddy, Ph.D., Vice President of Preclinical R&D, Unicycive
- Session Title: AKI: Clinical, Outcomes, and Trials - Management
- Poster Board: #SA-PO036
- Date/Time: October 26, 2024, from 10:00 a.m. – 12:00 p.m. PT
About Oxylanthanum Carbonate
Oxylanthanum carbonate is a novel phosphate binding agent that utilizes advanced nanoparticle technology to treat hyperphosphatemia in patients with chronic kidney disease (CKD). With over forty patents issued globally, OLC may offer advantages over current treatments by reducing the number and size of pills required for effective patient management. According to nephrologists, a critical unmet need in treating hyperphosphatemia involves minimizing the pill burden for better patient adherence.
Market Potential and Development Pathway
The market for treating hyperphosphatemia is estimated to surpass $2.5 billion, with a significant portion attributed to the United States. Unicycive is pursuing FDA approval for OLC through the 505(b)(2) pathway, having completed various studies, including a pivotal clinical trial with favorable outcomes regarding tolerability and efficacy.
Understanding Hyperphosphatemia
Hyperphosphatemia is a common complication in patients with End Stage Renal Disease (ESRD). If untreated, it can lead to serious conditions, including cardiovascular disease and complications associated with bone health. Efficient management of hyperphosphatemia focuses on lowering serum phosphate levels through dietary restrictions and the use of phosphate binding drugs, facilitating phosphate elimination.
UNI-494: A Novel Therapeutic Candidate
UNI-494 is an innovative therapeutic candidate that acts as a selective ATP-sensitive mitochondrial potassium channel activator. The drug is currently in clinical development, targeting acute kidney injury and related conditions. Following completion of a Phase 1 safety study, results are anticipated in the near future. UNI-494 has also received orphan drug designation from the FDA for preventing Delayed Graft Function (DGF) in kidney transplant patients.
Acute Kidney Injury and Delayed Graft Function Explained
Acute kidney injury (AKI) is characterized by a sudden decline in kidney function and is often precipitated by various factors such as sepsis or ischemia. DGF is a form of AKI that occurs post-kidney transplantation and may require dialysis. The presence of IRI is a significant factor contributing to AKI in this context. Strategies like ischemic preconditioning are being investigated to enhance renal protection.
About Unicycive Therapeutics
Unicycive Therapeutics is dedicated to developing innovative therapies for kidney disease. The company's lead candidate, OLC, aims to address hyperphosphatemia, while UNI-494 represents a new approach to mitigating acute kidney injury. Interested parties can reach out to the company for further inquiries.
Contact Information:
ir@unicycive.com
(650) 543-5470
Frequently Asked Questions
What is the purpose of Unicycive's poster presentations?
The presentations aim to share research findings on OLC and UNI-494, highlighting innovations in kidney disease treatment.
What are the main products being highlighted at ASN Kidney Week 2024?
Unicycive will showcase oxylanthanum carbonate (OLC) and UNI-494 during the event.
How does oxylanthanum carbonate benefit patients?
OLC reduces the pill burden for patients with CKD, potentially improving adherence to treatment regimens.
What is UNI-494's mechanism of action?
UNI-494 activates mitochondrial potassium channels to restore kidney function during AKI.
How can one obtain more information about Unicycive Therapeutics?
For more details, interested individuals can contact Unicycive Therapeutics directly at their investor relations email.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- atNorth Welcomes Jeff Kjeldsen as New Operations Director
- Market Movements: Tesla's Miss and Levi Strauss' Brand Evaluation
- Analysts React to Tesco's Mixed Guidance Update
- BlackRock Adjusts Shareholding in Novonesis for Growth Strategy
- Insight into Recent Transactions at Danske Bank A/S
- Revamping Expectations: AngioDynamics Prepares for Earnings Release
- Embrace Nature with miel's 2024 Autumn/Winter Apparel Line
- Czech Researchers Create Innovative Antibiotics to Combat Resistance
- SAP and Carahsoft Face Major Legal Challenges Amid Investigation
- Navigating Currency Fluctuations: Insights on the Yen's Movement
Recent Articles
- Kraig Biocraft Laboratories Enhances Spider Silk Production
- Flow Capital Secures $15 Million Credit Facility for Growth
- PDD Holdings Reports Lower Revenue Amidst Competition
- Iopofosine I-131 Presentations at International Workshop
- Market Insights: Investors Eye Nvidia Earnings and Rate Cuts
- Donald Trump's Investment Strategy in Dividend Kings
- Investing Insights: Billionaires Shifting from Nvidia
- Investing in Top Dividend Stocks: PepsiCo and BlackRock
- Exploring Alternatives to Vanguard S&P 500 ETF Investments
- Market Reactions to Upcoming Federal Reserve Rate Cuts
- Kvika Banki hf. Announces Share Buyback Details
- Sompo Partners with Palantir for AI Innovations
- Falco Resources Forms New Technical and Strategic Committees
- Nvidia's Anticipated Surge in Q2 Revenue Highlights AI Demand
- Fanhua to Release First Half 2024 Financial Results Soon
- OKX Introduces 'Earn DOGS Together' with 1 Billion Rewards
- Solidion Innovates EV Batteries with Strategic Partnerships
- Compass Diversified Appoints Stephen Keller as CFO
- Svitzer Group Board Transactions and Shareholder Insights
- Mattermost Appoints Leigh Dow as Chief Marketing Officer
- Alcohol-Based Markers Market Set to Reach USD 3.62 Billion
- Kefir Market Growth Prospects to Reach $4.9 Billion
- Decorative Laminates Market Growth to USD 11.58 Billion
- Aplastic Anemia Market Expected to Reach USD 10.8 Billion
- Kaldvik AS Reports Q2 2024 Results and Webcast Details
- WisdomTree Daily Fund Prices Overview
- Details on Tims China's Q2 2024 Results Conference Call
- ISS A/S Updates on Share Buyback Program Transactions
- Visa's Future: Growth Opportunities and Prospects
- Warren Buffett's Investment Strategy: Top Stocks Revealed
- Current Challenges Facing Germany's Economic Outlook
- Viking Therapeutics: A Promising Future in Metabolic Treatments
- AI as a Service Market Expected to Surpass $124.2 Billion
- Hair Wax Stick Market Growth Projected to Reach $402M
- IDEX Biometrics Registers Capital Increase and Share Placement
- Bitcoin's Market Potential Amid Uncertain Trends
- International Petroleum Corporation Announces Share Buyback Details
- Medigene AG Announces Share Capital Reduction Implementation
- International Petroleum Corporation Announces Share Buyback Results
- ANEW MEDICAL Inc. Achieves Financial Milestone
- Aurora Mobile Partners with Closeli for Visual Cloud Innovation
- Santech Holdings Launches $5 Million Share Buyback Plan
- Pandora Launches Major Share Buyback Programme
- Exploring the Vanguard S&P 500 Growth ETF Performance
- Danske Bank A/S Operational Update and Share Transactions
- Prepayments Update from Realkredit Danmark A/S
- Sydbank's Latest Share Buyback Transactions Update
- Three Reasons Why Nvidia Stock Will Soar Post-August
- Promising Growth Stocks: Palantir Technologies and Monday.com
- Stucco Market Forecast: $21 Billion Growth by 2032